Synonyms: Hengqu® | SHR-8735
hetrombopag is an approved drug (China (2021))
Compound class:
Synthetic organic
Comment: Hetrombopag is an orally bioavailable, non-peptide small‐molecule thrombopoietin receptor (TPOR/MPL) agonist, that was developed as a treatment for thrombocytopenia [1]. The parent compound is shown here. It is administered as the ethanolamine/olamine.
|
|
Bioactivity Comments |
Hetrombopag stimulates megakaryocyte proplatelet formation from human CB‐CD34+ cells in vitro [1]. At the molecular signalling level, it induces a concentration‐dependent increase in pSTAT3, pSTAT5 and pERK1/2 in human umbilical cord blood-derived CD34+ cells, and in this respect it is more potent than eltrombopag. We have been unable to find a binding affinity or agonist potency value for hetrombopag in the published literature. |
Selectivity at catalytic receptors | ||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|